Human kidney homotransplantation was first attempted on a large scale in 1962 and 1963. Even its most enthusiastic proponents could not then predict that this procedure would within five years become the preferred and the most effective way of treating patients with renal failure. Almost all previous trials had ended in the early death of the recipient [12] There are today only two patients still alive who were treated before 1962, one from Boston and the other from Paris; both received kidneys from fraternal twins. Immunosuppression was with total body radiation, a technique of host conditioning which has been replaced in most centers by drug therapy. In contrast, successes in the succeeding years have been reported by many authors [6,18,27,35,36,45,55,69,101].In this report, several issues will be reviewed on the basis of our earlier experience with human renal transplantation. The questions to be examined in distant retrospect concern the homograft rejection seen after clinical renal transplantation and the measures necessary to control and reverse this process; the life expectancy of patients brought through early rejection episodes; the effect of prospective histocompatibility matching upon survival; and the early and delayed influence of thymectomy upon kidney transplant function. More recent developments will also be mentioned including the use of heterologous antilymphocyte globulin (ALG) in man, the role of the